Magnesium Sulfate in Combination With Dexmedetomidine As Adjuvants to Levobupivacaine

Cairo University (CU)

Status and phase: Completed; Early Phase 1

Conditions: Spermatic Cord Block

Treatments: Drug: Control Test; Drug: magnesium sulphate; Drug: Dexmedetomidine; Drug: Dexmedetomidine and magnesium sulphate

Study type: Interventional

Funder types: Other

Identifiers

NCT04498351

N-19-2020

Details and patient eligibility

About

Using the spermatic cord block has been of great advantage, as it has been cost saving, efficient technique whether used inon its own or combination with a sedative or . Furthermore, it provides minimal cardiac risks, early case ambulation, satisfactory postoperative pain control, as well as a reduced hospital stay and cost. one of the major drawbacks of spermatic cord block is being a single injection technique, leading to a short postoperative analgesia duration. So, to overcome this flaw some adjuvants were proven to prolong the analgesia duration as Dexmetedomidine (Dex), and magnesium.

Full description

The technique of the spermatic cord block was first described in the 1960s by Earle AS.Using the spermatic cord block has been of great advantage, as it has been cost saving, efficient technique whether used inon its own or combination with a sedative or . Furthermore, it provides minimal cardiac risks, early case ambulation, satisfactory postoperative pain control, as well as a reduced hospital stay and cost. one of the major drawbacks of spermatic cord block is being a single injection technique, leading to a short postoperative analgesia duration. So, to overcome this flaw some adjuvants were proven to prolong the analgesia duration as Dexmetedomidine (Dex), and magnesium.

Enrollment: 130 patients

Sex: Male

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients aged from 18 to 60 years.
• ASA I-II.
• Undergoing Testicular Sperm Extraction Surgery.
• BMI from 18.5 to 30 kg/m2

Exclusion criteria

• Patient refusal
• Contraindications to regional anesthesia (bleeding disorders e.g. INR>1.5, PC<70%, platelet count<100 × 109, use of any anti-coagulants, local infection, etc.).
• Known allergy to local anesthetics.
• ASA III-IV.
• Patients aged less than 18 or more than 60.
• Body mass index >35.
• Patients with difficulty in evaluating their level of pain.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

130 participants in 4 patient groups, including a placebo group

cotrol group

Placebo Comparator group

Treatment:

Drug: Control Test

dexmedetomidine group

Active Comparator group

Treatment:

Drug: Dexmedetomidine

magnesium sulphate group

Active Comparator group

Treatment:

Drug: magnesium sulphate

dexmedetomidine and magnesium sulphate group

Active Comparator group

Treatment:

Drug: Dexmedetomidine and magnesium sulphate